|
Abstract
|
|
||
Pediatrics International |
||
| Original Article | ||
| Comparison of treatments of chronic
hepatitis B in children with lamivudine and
|
||
| Bunyamin Dikici,1
Mehmet Bosnak,1
Vuslat Bosnak,2
Abdullah Dagli,1
Mehmet Davutoglu,1
Rasit Vural Yagci3
and Kenan Haspolat1 |
||
Background: The aim of this study was to compare the
efficacy of the
Methods: Patients were evaluated in two groups
retrospectively. In group 1, 27 patients were simultaneously given
Results: In group 1 the initial mean value of alanine aminotransferase (ALT) was 121 ± 66 IU/L and decreased to 27.8 ± 11.5 IU/L; in group 2, initial mean values of ALT was 129 ± 46 IU/L and decreased to 60 ± 6 IU/L at the end of the twelfth month of the therapy (P< 0.05). Hepatitis B virus DNA (HBV-DNA) clearance was obtained in all group 1 patients and six of 13 patients in group 2 at the end of the therapy (P< 0.001). The rates of hepatitis B early (HBe) antigen clearance and anti-HBe seroconversion were 59 and 37% in group 1 and 46 and 30.7% in group 2 (P> 0.05). The number of patients with complete response was found to be 10 out of 27 (37%) in group 1 and four out of 13 cases (30.7%) in group 2, 6 months after the end of the therapy. There was no statistically significant difference between both groups (P> 0.05). Conclusion:
|
||
|
|
||
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.